June 2026
Neuroplasticity
What June 2026's 15 new studies found, synthesized from the papers below. All Neuroplasticity research →
The synthesis
Synthesized from 15 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Neuroplasticity, neural plasticity, brain plasticity, synaptic plasticity, neurogenesis, then ranked by relevance.
Research in June 2026 found that psilocybin and ketamine can enhance neuroplasticity in animal models and humans, with psilocybin reversing stress-induced neuroplastic deficits and ketamine promoting synaptic remodeling. However, microdosing psilocin did not increase neurogenesis in rats, and the evidence for endogenous DMT maintaining neuroplasticity remains mixed. The main caveat is that most findings come from preclinical studies, with limited and preliminary human data.
Confidence in the evidence
Low-Moderate- Multiple preclinical studies (RCTs in animals) show consistent positive effects of psilocybin and ketamine on neuroplasticity markers, but sample sizes are small and species are limited to rodents.
- One animal study on psilocin microdosing found null results, introducing inconsistency regarding dose and regimen.
- Human evidence is limited to case reports and reviews; no large-scale human RCTs on neuroplasticity were provided.
- Theoretical and review articles contribute to mechanistic understanding but do not provide direct empirical evidence.
How we rate confidence
Confidence reflects the strength of the underlying evidence, not whether the result is favorable. It weighs the number and size of studies, their design (randomized trials count for more than observational or single-case work), how consistently they point the same way, and their risk of bias.
Tiers run from Insufficient to High. High is rare in this field: small, early, or open-label studies land lower even when their direction is encouraging.
Evidence by study
Direction is each study's finding relative to your question: Supports, Opposes, No effect, Mixed, or Unclear.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Chronic psilocin microdosing produces limited behavioral effects and does not enhance neurogenesis in rats. 2026 | preclinical RCT | — | No effect | Chronic psilocin microdosing did not affect behavior or dentate gyrus cell proliferation in rats. |
| Ketamine renaissance: Expanding horizons from anesthesia to depression and pain 2026 | review | — | Supports | Ketamine enhances synaptic plasticity and modulates neuroinflammatory pathways, offering therapeutic promise for depression and pain. |
| Psilocybin reduces fear memory and restores neuroplasticity in the hippocampus and medial prefrontal cortex. 2026 | preclinical RCT | — | Supports | Psilocybin reduced fear memory and restored neuroplasticity in the hippocampus and medial prefrontal cortex in mice. |
| Art as Neuroplastogens 2026 | theoretical | — | Unclear | Proposes that algorithmic art can function as a non-pharmacological neuroplastogen via prediction-error signaling. |
| A Critical Evaluation of the Hypothesis that N,N-Dimethyltryptamine Maintains Neuroplasticity 2026 | review | — | Mixed | Evidence for endogenous DMT maintaining neuroplasticity is mixed and contested, with conflicting reports on brain concentrations. |
| Serotonergic psychedelics for Autism spectrum disorder: Neurobiological mechanisms and translational prospects. 2026 | review | — | Supports | Serotonergic psychedelics may enhance synaptic plasticity and modulate neuroplasticity in autism spectrum disorder. |
| Psilocybin restores behavioral and neuroplastic deficits induced by chronic stress in rats. 2026 | preclinical RCT | — | Supports | Psilocybin reversed anhedonia, induced hippocampal neurogenesis, and increased BDNF expression in stressed rats. |
| Ketamine and Evolving Neuroplasticity. 2026 | review | — | Supports | Ketamine promotes synaptic plasticity and neurogenesis through NMDA receptor antagonism and downstream signaling. |
| AMPA receptor modulation in depression: from molecular mechanisms of plasticity to therapeutic translation 2026 | review | — | Supports | AMPA receptor modulation, particularly via AMPAkines, shows antidepressant-like effects and enhances synaptic plasticity in preclinical studies. |
| From psychache to neuroplasticity: A unified rescue-repair model of Ketamine's anti-suicidal action. 2026 | theoretical | — | Unclear | Proposes a unified rescue-repair model of ketamine's anti-suicidal action involving neuroplasticity. |
| Prenatal stress, excitatory-inhibitory imbalance, and ADHD risk: a hypothesis-driven perspective on psilocybin-induced neuroplasticity. 2026 | theoretical | — | Unclear | Hypothesizes that psilocybin-induced neuroplasticity could theoretically modulate ADHD risk pathways, but evidence is preliminary. |
| Neural Attunement as a Post-Acute Framework for Stabilizing Neuroplasticity 2026 | theoretical | — | Unclear | Introduces the Neural Attunement Model for post-acute stabilization of neuroplasticity after psychedelics. |
| Ketamine infusion combined with accelerated sequential theta burst stimulation in multi-therapy-resistant bipolar depression: A case report. 2026 | case report | 1 | Supports | Ketamine combined with theta burst stimulation led to sustained remission and improved neuroplasticity markers (rMMN). |
| Synaptic Plasticity-Intrinsic Excitability and Antidepressant Discovery. 2026 | review | — | Supports | Antidepressant efficacy arises from coordinated engagement of synaptic plasticity and intrinsic excitability, with ketamine as a key example. |
| Optimized Oral Glutamatergic Augmentation in Refractory Home-Dominant Contamination Obsessive-Compulsive Disorder With Somatic, Affective, and Motivational Features: A Case Report of Incremental Functional Gains. 2026 | case report | 1 | Supports | A glutamatergic augmentation strategy improved symptoms, suggesting modulation of synaptic plasticity in OCD. |
Chronic psilocin microdosing did not affect behavior or dentate gyrus cell proliferation in rats.
preclinical RCT
Ketamine enhances synaptic plasticity and modulates neuroinflammatory pathways, offering therapeutic promise for depression and pain.
review
Psilocybin reduced fear memory and restored neuroplasticity in the hippocampus and medial prefrontal cortex in mice.
preclinical RCT
Proposes that algorithmic art can function as a non-pharmacological neuroplastogen via prediction-error signaling.
theoretical
Evidence for endogenous DMT maintaining neuroplasticity is mixed and contested, with conflicting reports on brain concentrations.
review
Serotonergic psychedelics may enhance synaptic plasticity and modulate neuroplasticity in autism spectrum disorder.
review
Psilocybin reversed anhedonia, induced hippocampal neurogenesis, and increased BDNF expression in stressed rats.
preclinical RCT
Ketamine promotes synaptic plasticity and neurogenesis through NMDA receptor antagonism and downstream signaling.
review
AMPA receptor modulation, particularly via AMPAkines, shows antidepressant-like effects and enhances synaptic plasticity in preclinical studies.
review
Proposes a unified rescue-repair model of ketamine's anti-suicidal action involving neuroplasticity.
theoretical
Hypothesizes that psilocybin-induced neuroplasticity could theoretically modulate ADHD risk pathways, but evidence is preliminary.
theoretical
Introduces the Neural Attunement Model for post-acute stabilization of neuroplasticity after psychedelics.
theoretical
Ketamine combined with theta burst stimulation led to sustained remission and improved neuroplasticity markers (rMMN).
case report · Sample size: 1
Antidepressant efficacy arises from coordinated engagement of synaptic plasticity and intrinsic excitability, with ketamine as a key example.
review
A glutamatergic augmentation strategy improved symptoms, suggesting modulation of synaptic plasticity in OCD.
case report · Sample size: 1
Points of agreement
- Psilocybin and ketamine enhance neuroplasticity in preclinical models, including synaptic remodeling, neurogenesis, and BDNF expression.
- Glutamatergic signaling (NMDA and AMPA receptors) is a key mechanism for neuroplasticity in depression and other disorders.
- The post-acute period after psychedelic administration may be important for stabilizing neuroplastic changes.
Conflicts
- Psilocin microdosing did not enhance neurogenesis in rats, whereas psilocybin at higher doses did, suggesting dose-dependent effects.
- Evidence for endogenous DMT's role in maintaining neuroplasticity is mixed, with some studies finding DMT in brain and others not.
Gaps
- Lack of large-scale human RCTs directly measuring neuroplasticity after psychedelic or ketamine treatment.
- Durability of neuroplastic changes beyond short-term follow-up is poorly characterized.
- Effects in vulnerable populations (e.g., adolescents, elderly) and across different doses and regimens are understudied.
- Standardized protocols for measuring neuroplasticity in humans are lacking.